These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14561693)

  • 1. The yin and yang of rheumatoid arthritis.
    Birmingham K
    J Clin Invest; 2003 Oct; 112(8):1126. PubMed ID: 14561693
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
    Brennan FM; Cope AP; Katsikis P; Gibbons DL; Maini RN; Feldmann M
    Chem Immunol; 1995; 60():48-60. PubMed ID: 7857528
    [No Abstract]   [Full Text] [Related]  

  • 3. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.
    Feldmann M; Maini RN
    Nat Med; 2003 Oct; 9(10):1245-50. PubMed ID: 14520364
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action.
    Feldmann M; Brennan F; Paleolog E; Taylor P; Maini RN
    Eur Cytokine Netw; 1997 Sep; 8(3):297-300. PubMed ID: 9346366
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor necrosis factor inhibitor therapy for rheumatoid arthritis.
    Naguwa SM
    Ann N Y Acad Sci; 2005 Jun; 1051():709-15. PubMed ID: 16127011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of tumor necrosis factor (TNF-alpha) in rheumatoid arthritis].
    Godyń-Swedzioł RM; Stańczyk J; Hilt J; Kowalski ML
    Przegl Lek; 2004; 61(2):90-3. PubMed ID: 15230148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Yin and Yang of TNF-{alpha} inhibition.
    Fiorentino DF
    Arch Dermatol; 2007 Feb; 143(2):233-6. PubMed ID: 17310003
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of anti-tumor necrosis factor on work disability.
    Verstappen SM; Jacobs JW; Hyrich KL
    J Rheumatol; 2007 Nov; 34(11):2126-8. PubMed ID: 17985411
    [No Abstract]   [Full Text] [Related]  

  • 9. Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.
    Williams RO; Feldmann M; Maini RN
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i75-80. PubMed ID: 11053094
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 11. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy.
    Kaur PP; Derk CT; Chatterji M; Dehoratius RJ
    J Rheumatol; 2004 Aug; 31(8):1663-5. PubMed ID: 15290751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab.
    Sturfelt G; Christensson B; Bynke G; Saxne T
    J Rheumatol; 2007 Nov; 34(11):2313-4. PubMed ID: 17985415
    [No Abstract]   [Full Text] [Related]  

  • 15. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor alpha therapy in rheumatoid arthritis: hitting two birds with one stone?
    Warrington KJ
    Arthritis Rheum; 2004 Jun; 51(3):309-10. PubMed ID: 15188311
    [No Abstract]   [Full Text] [Related]  

  • 17. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathogenesis of rheumatoid arthritis: targeting cytokines.
    Zwerina J; Redlich K; Schett G; Smolen JS
    Ann N Y Acad Sci; 2005 Jun; 1051():716-29. PubMed ID: 16127012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al.
    Dixon W; Silman A
    Arthritis Res Ther; 2006; 8(5):111. PubMed ID: 16911768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.